These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 27756582)

  • 1. Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors.
    Muthukaruppan A; Lasham A; Woad KJ; Black MA; Blenkiron C; Miller LD; Harris G; McCarthy N; Findlay MP; Shelling AN; Print CG
    Clin Breast Cancer; 2017 Apr; 17(2):139-153. PubMed ID: 27756582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neo-tanshinlactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha.
    Lin W; Huang J; Liao X; Yuan Z; Feng S; Xie Y; Ma W
    Pharmacol Res; 2016 Sep; 111():849-858. PubMed ID: 27491559
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Mitobe Y; Ikeda K; Suzuki T; Takagi K; Kawabata H; Horie-Inoue K; Inoue S
    Mol Cell Biol; 2019 Dec; 39(23):. PubMed ID: 31501276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen Receptor-α Quantification in Breast Cancer: Concordance Between Immunohistochemical Assays and mRNA-In Situ Hybridization for ESR1 Gene.
    Thomsen C; Nielsen S; Nielsen BS; Pedersen SH; Vyberg M
    Appl Immunohistochem Mol Morphol; 2020; 28(5):347-353. PubMed ID: 30920963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
    Hosey AM; Gorski JJ; Murray MM; Quinn JE; Chung WY; Stewart GE; James CR; Farragher SM; Mulligan JM; Scott AN; Dervan PA; Johnston PG; Couch FJ; Daly PA; Kay E; McCann A; Mullan PB; Harkin DP
    J Natl Cancer Inst; 2007 Nov; 99(22):1683-94. PubMed ID: 18000219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.
    Iwamoto T; Booser D; Valero V; Murray JL; Koenig K; Esteva FJ; Ueno NT; Zhang J; Shi W; Qi Y; Matsuoka J; Yang EJ; Hortobagyi GN; Hatzis C; Symmans WF; Pusztai L
    J Clin Oncol; 2012 Mar; 30(7):729-34. PubMed ID: 22291085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor α dependent regulation of estrogen related receptor β and its role in cell cycle in breast cancer.
    Madhu Krishna B; Chaudhary S; Mishra DR; Naik SK; Suklabaidya S; Adhya AK; Mishra SK
    BMC Cancer; 2018 May; 18(1):607. PubMed ID: 29843638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).
    Pentheroudakis G; Kotoula V; Eleftheraki AG; Tsolaki E; Wirtz RM; Kalogeras KT; Batistatou A; Bobos M; Dimopoulos MA; Timotheadou E; Gogas H; Christodoulou C; Papadopoulou K; Efstratiou I; Scopa CD; Papaspyrou I; Vlachodimitropoulos D; Linardou H; Samantas E; Pectasides D; Pavlidis N; Fountzilas G
    PLoS One; 2013; 8(7):e70634. PubMed ID: 23923010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
    Wu JR; Zhao Y; Zhou XP; Qin X
    Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.
    Kim C; Tang G; Pogue-Geile KL; Costantino JP; Baehner FL; Baker J; Cronin MT; Watson D; Shak S; Bohn OL; Fumagalli D; Taniyama Y; Lee A; Reilly ML; Vogel VG; McCaskill-Stevens W; Ford LG; Geyer CE; Wickerham DL; Wolmark N; Paik S
    J Clin Oncol; 2011 Nov; 29(31):4160-7. PubMed ID: 21947828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediagnostic Smoking Is Associated with Binary and Quantitative Measures of ER Protein and
    Butler EN; Bensen JT; Chen M; Conway K; Richardson DB; Sun X; Geradts J; Olshan AF; Troester MA
    Cancer Epidemiol Biomarkers Prev; 2018 Jan; 27(1):67-74. PubMed ID: 29133365
    [No Abstract]   [Full Text] [Related]  

  • 12. miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.
    Endo Y; Toyama T; Takahashi S; Yoshimoto N; Iwasa M; Asano T; Fujii Y; Yamashita H
    Endocr Relat Cancer; 2013 Feb; 20(1):91-102. PubMed ID: 23183268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular profiles of progesterone receptor loss in human breast tumors.
    Creighton CJ; Kent Osborne C; van de Vijver MJ; Foekens JA; Klijn JG; Horlings HM; Nuyten D; Wang Y; Zhang Y; Chamness GC; Hilsenbeck SG; Lee AV; Schiff R
    Breast Cancer Res Treat; 2009 Mar; 114(2):287-99. PubMed ID: 18425577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of gene expression induced by siRNA targeting of estrogen receptor alpha in MCF7 human breast cancer cells.
    Luqmani YA; Al Azmi A; Al Bader M; Abraham G; El Zawahri M
    Int J Oncol; 2009 Jan; 34(1):231-42. PubMed ID: 19082494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor alpha (ESR1)-signaling regulates the expression of the taxane-response biomarker PRP4K.
    Lahsaee S; Corkery DP; Anthes LE; Holly A; Dellaire G
    Exp Cell Res; 2016 Jan; 340(1):125-31. PubMed ID: 26712520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines.
    Wu Q; Guo L; Jiang F; Li L; Li Z; Chen F
    J Cell Mol Med; 2015 Dec; 19(12):2874-87. PubMed ID: 26416600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHRNA5 belongs to the secondary estrogen signaling network exhibiting prognostic significance in breast cancer.
    Shehwana H; Keskus AG; Ozdemir SE; Acikgöz AA; Biyik-Sit R; Cagnan I; Gunes D; Jahja E; Cingir-Koker S; Olmezer G; Sucularli C; Konu O
    Cell Oncol (Dordr); 2021 Apr; 44(2):453-472. PubMed ID: 33469842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup.
    Alles MC; Gardiner-Garden M; Nott DJ; Wang Y; Foekens JA; Sutherland RL; Musgrove EA; Ormandy CJ
    PLoS One; 2009; 4(3):e4710. PubMed ID: 19270750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
    Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
    Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSF Promotes ER-Positive Breast Cancer Progression via Posttranscriptional Regulation of
    Mitobe Y; Iino K; Takayama KI; Ikeda K; Suzuki T; Aogi K; Kawabata H; Suzuki Y; Horie-Inoue K; Inoue S
    Cancer Res; 2020 Jun; 80(11):2230-2242. PubMed ID: 32213542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.